@article{TGH5056,
author = {Alok K. Shah and Virendra Joshi and Gunter Hartel and Andrew P. Barbour and Michelle M. Hill},
title = {To BE or not to BE: non-invasive screening for Barrett’s esophagus, dysplasia and adenocarcinoma},
journal = {Translational Gastroenterology and Hepatology},
volume = {4},
number = {0},
year = {2019},
keywords = {},
abstract = {The EsophaCap™ DNA methylation biomarker validation study by Wang, Kambhampati and colleagues (1) follows a spade of reports (summarized in Table 1) aiming to develop screening tests for Barrett’s esophagus (BE). BE is a non-malignant metaplastic condition with little or no clinical symptoms. Arguably, the main importance of diagnosing BE is the increased risk of the patient to progress to esophageal adenocarcinoma (EAC).},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/5056}
}